Dako is integrating with Agilent on November 1, 2016. Find out what this means to you as a customer.
Leading the way
in PD-L1 testing
The only companion diagnostic to aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).
New Dako Omnis RTU antibodies
Introduction of 13 new high quality FLEX RTU antibodies for Dako Omnis.
PD-L1 IHC 28-8 pharmDx training
Learn how to evaluate PD-L1 expression in both non-squamous NSCLC and melanoma patients for OPDIVO® (nivolumab).
Review of Breast Cancer Diagnosis
In collaboration with leading experts, Agilent publishes a new comprehensive review on breast cancer diagnostic testing.
Results you can trust
The first and only FDA-approved PD-L1 test for use in both non-squamous NSCLC and melanoma for OPDIVO® (nivolumab).
Dako is integrating with Agilent
Read here what this means to you as a customer from November 1st.
2016 Product Catalog
The 2016 Pathology Product Catalog is now available for download.
Events and Congresses
Meet us at congresses and events around the world.